SLC6A3 and Parkinson disease: Compounds thatare able to block the dopamine transporter (DAT) have been suggested to be moreuseful in treating the motor symptoms in PD, as opposed to norepinephrine andserotonin re-uptake inhibitors.75 Additionally, compounds with the ability to block DAT may also haveneuroprotective activity.76NGP1-01 (Figure 11) wasrecently shown to block dopamine re-uptake in murine synaptosomes, with anIC50 of 57 μM.